ImmuCell Q2 FY26 net income more than doubled to 1.84 million; revenue rises 11.5% to 7.2 million

Reuters2026/08/13 20:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ImmuCell posted GAAP net income of $1.8 million for Q2 2026, up from $502,000 a year earlier; diluted EPS was $0.20.
Revenue rose 11.5% to $7.2 million, while gross margin fell 9.8 percentage points to 33.9%.
Results included a one-time $2 million legal settlement from a former Re-Tain contract manufacturer, booked as lower operating expenses.
Non-GAAP adjusted EBITDA increased to $2.7 million from $1.4 million in the prior-year quarter.
Board authorized a two-phase First Defense capacity expansion: about $3.5 million for freeze-drying, then about $4.5 million for liquid processing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809860) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ImmuCell Q2 FY26 net income more than doubled to 1.84 million; revenue rises 11.5% to 7.2 million

You may also like

Crypto prices